BURDEN, RISK FACTORS AND PREVENTION OF RESPIRATORY INFECTIONS AND INFECTIOUS DISEASES IN CHILDREN
Associate Professor Hannah Moore OAM
Program Head, Infection and Vaccines,
The Kids Research Institute Australia &
Associate Professor at the School of Population Health, Curtin University
Western Australia
RESEARCHER PROFILE (Filmed in Perth, Western Australia | December 2024)
A/Prof Hannah Moore OAM is an infectious disease epidemiologist; Co-Head of the Infectious Disease Epidemiology team within the Wesfarmers Centre of Vaccines and Infectious Diseases at The Kids Research Institute Australia and Associate Professor at the School of Population Health, Curtin University in Western Australia.
Her passion for research involves using population-based data to investigate how to recognise, prevent and reduce serious respiratory and other infectious diseases in children through estimating burden of disease and evaluating the effectiveness of vaccination programs. She has developed expertise in the epidemiology of Respiratory Syncytial Virus (RSV) in young children, where her research was pivotal in WA Governments’ decision to establish the first and most comprehensive RSV infant immunisation program in the nation. Raising awareness of RSV, understanding community burden and evaluating the impact of prevention measures is now a major focus of her research program. She has previously contributed to state and national influenza vaccination policy.
In 2020 A/Prof Moore joined the Strep A Vaccine Global Consortium (SAVAC) to increase knowledge and awareness of the global burden of Group A Streptococcal diseases. She now holds an activity lead position in the US$11M-funded SAVAC 2.0.
A/Prof Moore has been awarded more than $19M in competitive research grants, co-authored more than 140 papers, was TEDxPerth 2018 speaker, recipient of a WA Young Tall Poppy Award (2013) and the WA Premiers Science Early Career Scientist Award (2015). In 2024, she was honoured with a Medal of the Order of Australia for her service to epidemiology as a researcher.
Editor’s note: At the time of recording in September 2024, A/Prof Hannah Moore makes reference to needing a national RSV immunisation program. Efforts by her and others in campaigning were successful and in November 2024 the Australian National Immunisation Program was updated to include RSV from 2025. https://www.health.gov.au/news/national-immunisation-program-update-rsv-vaccine#:~:text=The%20inclusion%20of%20the%20RSV,announced%20as%20soon%20as%20possible.
https://orcid.org/0000-0003-4920-9991
-
Biomarkers for early sepsis detection
Dr Gabrielle Briggs is a biomedical scientist dedicated to finding smarter, faster ways to diagnose and treat life threatening complications in critically ill patients. Dr Briggs established a research laboratory embedded within the John Hunter Hospital – one of the busiest major trauma centres in NSW. Dr Briggs works alongside surgeons, intensivists, and pathologists to turn complex clinical problems into practical research solutions. Her work spans two major programs: developing a rapid diagnostic test to detect bacterial infections in blood before sepsis takes hold, and exploring mitochondrial transplantation as a novel therapy to rescue injured tissues after trauma and ischaemia.
-
Environmental exposure to function of lung epithelial stem cell biology
Dr Clare Weeden has recently commenced as a Laboratory Head at WEHI in 2025, supported by the CSL Centenary Fellowship.
Dr Weeden specialises in lung epithelial cell biology in the context of homeostasis, inflammation, and lung cancer, particularly in people who don’t smoke. Her work endeavours to understand how past environmental exposures shape the responses of lung cells and the molecular mechanisms underlying this cellular recall, with the aim to develop novel early detection strategies for lung disease.
-
Personalised approaches to lung therapy
Dr. Adams’ research focus is on lung cancer, which is the deadliest of all cancers worldwide. He is working towards developing personalised approaches to pinpoint a therapy that is going to be most effective for the person with that disease. Dr. Adams’ research is focusing on chemotherapy and targeted therapy, and he is trying to identify upfront which of those tumours are likely to be resistant to the therapy. He then identifies strategies that will resensitize or increase the sensitivity of the tumour to the standard of care that is targeted therapy or chemotherapy.
